Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Rentschler Kicks Off Expansion at U.S. Facility | Contract Pharma
Breaking News

Rentschler Kicks Off Expansion at U.S. Facility

New 500 L bioreactor in operation mid-2020 at U.S. site.

Rentschler Biopharma SE, a contract development and manufacturing organization (CDMO) for biopharmaceuticals, is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a single-use bioreactor for the 93,000 square foot facility in Milford, MA, in the Greater Boston area.
 
The XDR-500 bioreactor, with a working volume of 100-500 L and down stream process capabilities of 2-8 g/L, is part of the state-of-the-art GMP facility suite concept. The system is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. With its innovative and highly flexible business model, the Milford site is already taking on new projects, including complex and difficult-to-manufacture proteins, e.g. multispecific antibodies.
 
Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Both, in Europe and the U.S., Rentschler Biopharma will be able to leverage its client-centric approach and expertise in advanced technologies to facilitate the robust and scalable production of complex biomolecules.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters